Skip to main content

Fiscal Wizard · Single-issue tearsheet

PBLS / Jun 20, 2026 Run #7265

PBLS

Parabilis Medicines, Inc.

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Composite verdict

F 23.2 / 100
Bearish setup · Trend Following 1 driver · 1 gate blocking
  • Parabolic SAR Flip
Consider long put target Δ ~0.50 · ~35 DTE Bearish setup, Grade C → ITM put target

Industry rank 233rd of 598 in Biotechnology

rescore-sweep
Technical synthesis
Bull 0%Evidence: Low · 1 signals100% Bear
Momentum Bearish 32Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

0.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Greenblatt EY 75
Return on Capital Employed 0
Return on Assets 0
Greenblatt ROC 0

Technicals Neutral

46.5 / 100

Bearish setup leads (Parabolic SAR Flip). · 43 signals shown.

Strongest
Weakest
Parabolic SAR Flip 19

Risk Gates

1 blocking 2 caution

1 guard active — no matching signal fired this run.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Sloan Ratio Caution

Visual accruals-quality flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for PBLS.